Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Meritage Portfolio Management

Meritage Portfolio Management decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 661 shares of the medical equipment provider’s stock after selling 90 shares during the period. Meritage Portfolio Management’s holdings in Intuitive Surgical were worth $223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares in the last quarter. Jennison Associates LLC grew its stake in Intuitive Surgical by 6.4% in the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after acquiring an additional 274,692 shares during the period. Invesco Ltd. increased its holdings in Intuitive Surgical by 6.6% in the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after acquiring an additional 232,205 shares in the last quarter. Northern Trust Corp increased its holdings in Intuitive Surgical by 3.4% in the 3rd quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock worth $1,027,230,000 after acquiring an additional 115,059 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Intuitive Surgical by 0.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,030,415 shares of the medical equipment provider’s stock worth $593,470,000 after acquiring an additional 17,477 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $375.33 on Friday. The firm has a market capitalization of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.36. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The firm’s 50-day moving average is $386.19 and its two-hundred day moving average is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the prior year, the firm earned $1.00 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. Analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research report on Friday, January 19th. BTIG Research upped their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Jefferies Financial Group boosted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Raymond James lifted their price target on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Finally, Citigroup upped their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Insider Activity

In related news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 249,418 shares of company stock worth $96,300,959. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.